$LONA News

Piper Sandler Initiates Coverage On LeonaBio with Overweight Rating, Announces Price Target of $20

LeonaBio (NASDAQ:LONA) Beats Q1 Loss Estimates as Phase 3 Breast Cancer Trial Enrollment Expands

LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate

LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcript

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

LeonaBio Q4 EPS $(2.77) Misses $(0.84) Estimate

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

LeonaBio Files Prospectus For Offering Up To 58.5M Shares For Potential Sale By Selling Stockholders

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer - Slideshow

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Athira Pharma Announces Reverse Stock Split

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

This Athira Pharma Insider Increased Their Holding By 111% Last Year

Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates